<DOC>
	<DOCNO>NCT01603082</DOCNO>
	<brief_summary>The purpose study assess pharmacodynamic effect ticagrelor ACS patient undergo Ad Hoc PCI</brief_summary>
	<brief_title>Ad Hoc Percutaneous Coronary Intervention Study Acute Coronary Syndrome Patients</brief_title>
	<detailed_description>A randomized , open-label , multiple-center , parallel group study compare platelet inhibition VerifyNow assay ticagrelor versus clopidogrel troponin negative Acute Coronary Syndrome ( ACS ) subject undergoing Ad Hoc percutaneous coronary intervention ( PCI )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision sign date informed consent initiation studyrelated procedure Male female patient age 18 year older Documented acute coronary syndrome troponin negative undergoing Ad Hoc percutaneous coronary intervention ( PCI ) Females must post menopausal surgically sterile Taking aspirin antiplatelet medication Use thienopyridine ticagrelor within 7 day prior randomization Any indication oral anticoagulant ( e.g. , atrial fibrillation , mitral stenosis prosthetic heart valve ) Contraindication ticagrelor clopidogrel administer Patient require dialysis History intolerance allergy aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>